- Home
- NKSH vs ELDN Comparison
NKSH vs ELDN Comparison
Compare NKSH & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- ELDN
- Stock Information
- Founded
- NKSH 1891
- ELDN 2004
- Country
- NKSH United States
- ELDN United States
- Employees
- NKSH N/A
- ELDN N/A
- Industry
- NKSH Major Banks
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- ELDN Health Care
- Exchange
- NKSH Nasdaq
- ELDN Nasdaq
- Market Cap
- NKSH 172.6M
- ELDN 202.4M
- IPO Year
- NKSH N/A
- ELDN N/A
- Fundamental
- Price
- NKSH $31.30
- ELDN $2.65
- Analyst Decision
- NKSH Strong Buy
- ELDN Strong Buy
- Analyst Count
- NKSH 1
- ELDN 2
- Target Price
- NKSH $38.00
- ELDN $12.50
- AVG Volume (30 Days)
- NKSH 10.8K
- ELDN 662.1K
- Earning Date
- NKSH 10-23-2025
- ELDN 08-14-2025
- Dividend Yield
- NKSH 4.85%
- ELDN N/A
- EPS Growth
- NKSH 15.57
- ELDN N/A
- EPS
- NKSH 1.77
- ELDN 0.21
- Revenue
- NKSH $49,801,000.00
- ELDN N/A
- Revenue This Year
- NKSH $2.95
- ELDN N/A
- Revenue Next Year
- NKSH $9.97
- ELDN N/A
- P/E Ratio
- NKSH $17.57
- ELDN $12.17
- Revenue Growth
- NKSH 16.22
- ELDN N/A
- 52 Week Low
- NKSH $23.75
- ELDN $2.38
- 52 Week High
- NKSH $32.89
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- NKSH 62.67
- ELDN 43.94
- Support Level
- NKSH $30.52
- ELDN $2.54
- Resistance Level
- NKSH $31.40
- ELDN $2.84
- Average True Range (ATR)
- NKSH 0.71
- ELDN 0.13
- MACD
- NKSH 0.08
- ELDN 0.03
- Stochastic Oscillator
- NKSH 88.51
- ELDN 42.24
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.